Favorable response to disease modifying treatments in Chinese patients with relapsing multiple sclerosis - results from a prospective registry in Hong Kong

2018 ◽  
Author(s):  
Chung Kwan Au ◽  
Ng Pui Yung ◽  
Alexander Y. Lau
Keyword(s):  
Multiple Sclerosis ◽  
Hong Kong ◽  
Chinese Patients ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis

scholarly journals The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments

2020 ◽  
Vol 13 (5) ◽  
pp. 583-597
Author(s):  
Edward J. D. Webb ◽  
David Meads ◽  
Ieva Eskytė ◽  
Helen L. Ford ◽  
Hilary L. Bekker ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying ◽  
The Impact ◽  
Relapsing Multiple Sclerosis

scholarly journals Optimizing treatment strategies in paediatric, adult and late-onset multiple sclerosis

Brain ◽  
2020 ◽  
Vol 143 (10) ◽  
pp. 2866-2868
Author(s):  
Cristina Gaudioso ◽  
Robert T Naismith
Keyword(s):  
Multiple Sclerosis ◽  
Late Onset ◽  
Treatment Strategies ◽  
Disability Progression ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
Relapsing Multiple Sclerosis

This scientific commentary refers to ‘Disease-modifying drugs can reduce disability progression in paediatric, adult and late-onset relapsing multiple sclerosis’, by Amato etal. (doi:10.1093/brain/awaa251).

scholarly journals High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis

2018 ◽  
Vol 4 (3) ◽  
pp. 205521731878869 ◽  
Author(s):  
Alexander Lau ◽  
Wei Qiu ◽  
Allan Kermode ◽  
Cheryl Au ◽  
Angel Ng ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cross Sectional Study ◽  
Chinese Patients ◽  
Virus Antibody ◽  
Cross Sectional ◽  
John Cunningham Virus ◽  
High Prevalence ◽  
Scale Scores ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients

We performed a cross-sectional study in 123 Chinese multiple sclerosis patients residing in Hong Kong to evaluate their anti-John Cunningham virus status using STRATIFY JCV DxSelect assays. Anti-John Cunningham virus antibody was present in 98/123 (80%) subjects, among which 75/98 (77%) had an anti-John Cunningham virus index ≥1.5. Anti-John Cunningham virus antibody seropositivity was not correlated with age, disease duration, Expanded Disability Status Scale scores, types of multiple sclerosis (relapsing vs progressive), or disease-modifying treatments used. We found a very high seroprevalence and index of anti-John Cunningham virus antibodies in Chinese multiple sclerosis patients, which may impact the risk assessment and recommendation of disease-modifying treatments in this population.

Sign in / Sign up

Export Citation Format

Share Document